The medical foods for orphan diseases market size is expected to see strong growth in the next few years. It will grow to $1.82 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, healthcare system integration, emerging technologies in food science, precision nutrition, increased patient demand. Major trends in the forecast period include long-term efficacy studies, disease-specific formulations, education and training programs, focus on gut microbiome, nutritional supplements innovation.
The anticipated growth in the medical foods for orphan diseases market is driven by the increasing incidence of orphan diseases, also known as rare diseases, which affect a relatively small number of individuals within a population. These medical conditions necessitate specialized nutritional interventions, and medical foods play a crucial role in meeting the specific dietary requirements of patients with orphan diseases. The rise in the prevalence of orphan diseases, such as non-Hodgkin lymphoma and idiopathic pulmonary fibrosis, contributes to the expansion of the medical foods for orphan diseases market. For example, in January 2023, the American Cancer Society reported that non-Hodgkin lymphoma accounted for approximately 4% of cancer cases in the United States, with an estimated 80,550 new diagnoses in 2023. Additionally, a research study published in September 2022 revealed an increasing prevalence of idiopathic pulmonary fibrosis, reaching 36 cases per 100,000 people in 2021.
The growth of the medical foods for orphan diseases market is also fueled by the increasing incidence of chronic diseases. Chronic diseases, characterized by their long-lasting nature, lasting for three months or more, drive the demand for medical foods to address specific nutritional deficiencies and metabolic imbalances associated with these conditions. The World Health Organization (WHO) reported in September 2023 that chronic diseases contribute significantly to global mortality, with 41 million deaths annually, representing 74% of all fatalities. The specific breakdown includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. This increasing incidence of chronic diseases underscores the growing need for medical foods in managing and improving outcomes for individuals with orphan diseases.
Product innovation is a prominent trend gaining traction in the medical foods for orphan diseases market, with major companies strategically introducing innovative products to solidify their market positions. Notably, in October 2022, Relief Therapeutics, a Switzerland-based biopharmaceutical company, unveiled PKU GOLIKE, a groundbreaking medical food product developed with the company's patented Physiomimic Technology platform. This innovation targets the dietary management of phenylketonuria (PKU), an inherited rare disorder. PKU GOsuch as stands out as the first prolonged-release amino acid product, featuring a specialized coating that ensures the physiological absorption of amino acids while concealing the unpleasant taste, odor, and aftertaste associated with these compounds. The product is classified as a phenylalanine-free food designed for special medical purposes (FSMP) in the United States.
Major players in the medical foods for orphan diseases market are actively involved in the development of PKU GOLIKE, a revolutionary product tailored for managing symptoms of phenylketonuria (PKU). Launched by Relief Therapeutics in October 2022, PKU GOsuch as represents a phenylalanine-free food created for special medical purposes (FSMP). It is the first prolonged-release amino acid supplement, leveraging Relief Therapeutics' patented physiomimic technology platform to ensure physiological amino acid absorption, mimicking the natural protein absorption process.
In July 2023, Pentec Health, a US-based company specializing in innovative medication management solutions for patients with complex medical needs, acquired ZOIA Pharma for an undisclosed amount. This acquisition is intended to enhance Pentec Health's medical food services as a Complex Care Provider, ensuring that ZOIA Pharma customers can access innovative solutions for managing phenylketonuria (PKU) while addressing common patient concerns. ZOIA Pharma is a US-based organization dedicated to developing medical foods specifically for the treatment of orphan diseases.
Major companies operating in the medical foods for orphan diseases market include Nestle S.A., Abbott Laboratories Inc., Danone S.A., Ajinomoto Co. Inc., Meiji Holdings Co. Ltd., Fresenius Kabi AG, BioMarin Pharmaceutical Inc., Halyard Health, Alfasigma spA, Ultragenyx Pharmaceutical Inc., Immedica Group AB, Vitaflo International Ltd., Leadiant Biosciences Inc., Alcresta Therapeutics Inc., Cambrooke Therapeutics Inc., Primus Pharmaceuticals Inc., CANbridge Pharmaceuticals Inc., Cerecin Inc., AMNIOX Medical Inc., Targeted Medical Pharma Inc., Solace Nutrition LLC, Orphan Therapeutics LLC, Metagenics Inc., Farma Genetics Inc.
North America was the largest region in the medical foods for orphan diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medical foods for orphan diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical foods for orphan diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Specialized nutritional products tailored for orphan diseases encompass medical foods designed to address the distinct dietary requirements of individuals affected by rare, genetic, or orphan diseases. These products, available in pill, powder, liquid, and other forms, serve as targeted solutions for patients dealing with rare orphan diseases.
Medical food pills represent specific oral formulations crafted to deliver precise nutrients, dietary components, or therapeutic agents in a convenient pill format. These pills aim to meet unique nutritional needs and tackle metabolic imbalances associated with orphan diseases. Administered orally and through enteral routes, these medical foods play a crucial role in the treatment of conditions such as phenylketonuria, tyrosinemia, eosinophilic esophagitis, food protein-induced enterocolitis syndrome (FPIES), maple syrup urine disease (MSUD), homocystinuria, and others. These specialized products are available for purchase online, through institutes, and in retail stores, catering to the needs of individuals grappling with orphan diseases.
The medical foods for orphan diseases treatment market research report is one of a series of new reports that provides medical foods for orphan diseases treatment market statistics, including the medical foods for orphan diseases treatment industry's global market size, regional shares, competitors with medical foods for orphan diseases treatment market share, detailed medical foods for orphan diseases treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the medical foods for orphan diseases treatment industry. This medical foods for orphan diseases treatment market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The medical foods for orphan diseases market consist of sales of nutritionally complete formulas and nutritionally incomplete formulas. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Medical Foods For Orphan Diseases Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on medical foods for orphan diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for medical foods for orphan diseases? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medical foods for orphan diseases market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Pills; Powder; Liquid; Other Products2) By Route of Administration: Oral; Enteral
3) By Applications: Phenylketonuria; Tyrosinemia; Eosinophilic esophagitis; Food Protein-Induced Enterocolitis Syndrome (FPIES); Maple Syrup Urine Disease (MSUD); Homocystinuria; Other Applications
4) By Sales Channel: Online Sales; Institutional Sales; Retail Sales
Subsegments:
1) By Pills; Tablets; Capsules2) By Powder: Protein Powders; Nutritional Supplement Powders
3) By Liquid: Ready-To-Drink Formulas; Liquid Nutritional Supplements
4) By Other Products: Nutritional Bars; Fortified Foods; Ready-To-Use Therapeutic Foods
Key Companies Mentioned: Nestle S.A.; Abbott Laboratories Inc.; Danone S.A.; Ajinomoto Co. Inc.; Meiji Holdings Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Nestle S.A.
- Abbott Laboratories Inc.
- Danone S.A.
- Ajinomoto Co. Inc.
- Meiji Holdings Co. Ltd.
- Fresenius Kabi AG
- BioMarin Pharmaceutical Inc.
- Halyard Health
- Alfasigma spA
- Ultragenyx Pharmaceutical Inc.
- Immedica Group AB
- Vitaflo International Ltd.
- Leadiant Biosciences Inc.
- Alcresta Therapeutics Inc.
- Cambrooke Therapeutics Inc.
- Primus Pharmaceuticals Inc.
- CANbridge Pharmaceuticals Inc.
- Cerecin Inc.
- AMNIOX Medical Inc.
- Targeted Medical Pharma Inc.
- Solace Nutrition LLC
- Orphan Therapeutics LLC
- Metagenics Inc.
- Farma Genetics Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | February 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 1.42 Billion |
Forecasted Market Value ( USD | $ 1.82 Billion |
Compound Annual Growth Rate | 6.4% |
Regions Covered | Global |
No. of Companies Mentioned | 24 |